BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ruys AT, van Haelst S, Busch OR, Rauws EA, Gouma DJ, van Gulik TM. Long-term survival in hilar cholangiocarcinoma also possible in unresectable patients. World J Surg. 2012;36:2179-2186. [PMID: 22569746 DOI: 10.1007/s00268-012-1638-5] [Cited by in Crossref: 36] [Cited by in F6Publishing: 35] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Weijer R, Broekgaarden M, Krekorian M, Alles LK, van Wijk AC, Mackaaij C, Verheij J, van der Wal AC, van Gulik TM, Storm G, Heger M. Inhibition of hypoxia inducible factor 1 and topoisomerase with acriflavine sensitizes perihilar cholangiocarcinomas to photodynamic therapy. Oncotarget 2016;7:3341-56. [PMID: 26657503 DOI: 10.18632/oncotarget.6490] [Cited by in Crossref: 32] [Cited by in F6Publishing: 30] [Article Influence: 6.4] [Reference Citation Analysis]
2 Coelen RJS, de Keijzer MJ, Weijer R, Loukachov VV, Wiggers JK, Mul FPJ, van Wijk ACWA, Fong Y, Heger M, van Gulik TM. In vitro detection of cholangiocarcinoma cells using a fluorescent protein-expressing oncolytic herpes virus. Cancer Gene Ther 2017;24:227-32. [PMID: 28409558 DOI: 10.1038/cgt.2017.11] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
3 Li QJ, Zhou ZG, Lin XJ, Lao XM, Cui BK, Li SP. Clinical practice of basin-shaped hepaticojejunostomy following hilar resection of stage III/IV hilar cholangiocarcinoma. BMC Gastroenterol 2019;19:99. [PMID: 31221103 DOI: 10.1186/s12876-019-1012-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
4 Engelbrecht MR, Katz SS, van Gulik TM, Laméris JS, van Delden OM. Imaging of Perihilar Cholangiocarcinoma. American Journal of Roentgenology 2015;204:782-91. [DOI: 10.2214/ajr.14.12830] [Cited by in Crossref: 36] [Cited by in F6Publishing: 8] [Article Influence: 6.0] [Reference Citation Analysis]
5 Sakata T, Yoshikawa T, Nomi T, Matsuo Y, Kamitani N, Hokuto D, Sho M. Unresectable hilar cholangiocarcinoma treated with chemoradiotherapy: a 9-year survival case. Int Cancer Conf J 2021;10:41-5. [PMID: 33489700 DOI: 10.1007/s13691-020-00445-z] [Reference Citation Analysis]
6 Olthof PB, Coelen RJS, Wiggers JK, Groot Koerkamp B, Malago M, Hernandez-Alejandro R, Topp SA, Vivarelli M, Aldrighetti LA, Robles Campos R, Oldhafer KJ, Jarnagin WR, van Gulik TM. High mortality after ALPPS for perihilar cholangiocarcinoma: case-control analysis including the first series from the international ALPPS registry. HPB (Oxford). 2017;19:381-387. [PMID: 28279621 DOI: 10.1016/j.hpb.2016.10.008] [Cited by in Crossref: 53] [Cited by in F6Publishing: 49] [Article Influence: 13.3] [Reference Citation Analysis]
7 Ruys AT, Heuts SG, Rauws EA, Busch OR, Gouma DJ, van Gulik TM. Delay in surgical treatment of patients with hilar cholangiocarcinoma: does time impact outcomes? HPB (Oxford) 2014;16:469-74. [PMID: 24033549 DOI: 10.1111/hpb.12156] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
8 Olthof PB, Coelen RJ, Heger M, Klümpen HJ, Rauws EA, van Gulik TM. Emerging local ablative therapies for unresectable perihilar cholangiocarinoma: Time for re-appraisal. United European Gastroenterol J 2017;5:455-7. [PMID: 28507759 DOI: 10.1177/2050640616686857] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
9 van Vugt JLA, Gaspersz MP, Coelen RJS, Vugts J, Labeur TA, de Jonge J, Polak WG, Busch ORC, Besselink MG, IJzermans JNM, Nio CY, van Gulik TM, Willemssen FEJA, Groot Koerkamp B. The prognostic value of portal vein and hepatic artery involvement in patients with perihilar cholangiocarcinoma. HPB (Oxford). 2018;20:83-92. [PMID: 28958483 DOI: 10.1016/j.hpb.2017.08.025] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.8] [Reference Citation Analysis]
10 Gaspersz MP, Buettner S, van Vugt JLA, Roos E, Coelen RJS, Vugts J, Belt EJ, de Jonge J, Polak WG, Willemssen FEJA, van Gulik TM, IJzermans JNM, Groot Koerkamp B. Conditional survival in patients with unresectable perihilar cholangiocarcinoma. HPB (Oxford) 2017;19:966-71. [PMID: 28754366 DOI: 10.1016/j.hpb.2017.07.004] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
11 Gomez D, Patel P, Lacasia-purroy C, Byrne C, Sturgess R, Palmer D, Fenwick S, Poston G, Malik H. Impact of specialized multi-disciplinary approach and an integrated pathway on outcomes in hilar cholangiocarcinoma. European Journal of Surgical Oncology (EJSO) 2014;40:77-84. [DOI: 10.1016/j.ejso.2013.10.009] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 2.6] [Reference Citation Analysis]
12 Coelen RJ, Ruys AT, Wiggers JK, Nio CY, Verheij J, Gouma DJ, Besselink MG, Busch OR, van Gulik TM. Development of a Risk Score to Predict Detection of Metastasized or Locally Advanced Perihilar Cholangiocarcinoma at Staging Laparoscopy. Ann Surg Oncol. 2016;23:904-910. [PMID: 27586005 DOI: 10.1245/s10434-016-5531-6] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
13 Corvino F, Centore L, Soreca E, Corvino A, Farbo V, Bencivenga A. Percutaneous "Y" biliary stent placement in palliative treatment of type 4 malignant hilar stricture. J Gastrointest Oncol 2016;7:255-61. [PMID: 27034794 DOI: 10.3978/j.issn.2078-6891.2015.069] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
14 Pak K, Kim S, Kim IJ, Kim DU, Kim K, Kim H, Kim SJ. Splenic FDG uptake predicts poor prognosis in patients with unresectable cholangiocarcinoma. Nuklearmedizin 2018;53:26-31. [DOI: 10.3413/nukmed-0566-13-03] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
15 Donati M, Stavrou GA, van Gulik TM, Oldhafer KJ. Associating liver partition and portal vein ligation for staged hepatectomy for Klatskin tumours: hinc sunt leones! ANZ J Surg 2015;85:3-4. [PMID: 25759885 DOI: 10.1111/ans.12893] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
16 van Vugt JLA, Gaspersz MP, Vugts J, Buettner S, Levolger S, de Bruin RWF, Polak WG, de Jonge J, Willemssen FEJA, Groot Koerkamp B, IJzermans JNM. Low Skeletal Muscle Density Is Associated with Early Death in Patients with Perihilar Cholangiocarcinoma Regardless of Subsequent Treatment. Dig Surg. 2019;36:144-152. [PMID: 29455204 DOI: 10.1159/000486867] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 4.3] [Reference Citation Analysis]
17 Inchingolo R, Acquafredda F, Ferraro V, Laera L, Surico G, Surgo A, Fiorentino A, Marini S, de'Angelis N, Memeo R, Spiliopoulos S. Non-surgical treatment of hilar cholangiocarcinoma. World J Gastrointest Oncol 2021; 13(11): 1696-1708 [DOI: 10.4251/wjgo.v13.i11.1696] [Reference Citation Analysis]
18 Ruys AT, Busch OR, Rauws EA, Gouma DJ, van Gulik TM. Prognostic impact of preoperative imaging parameters on resectability of hilar cholangiocarcinoma. HPB Surg 2013;2013:657309. [PMID: 23861556 DOI: 10.1155/2013/657309] [Cited by in Crossref: 14] [Cited by in F6Publishing: 18] [Article Influence: 1.8] [Reference Citation Analysis]
19 Hu HJ, Mao H, Shrestha A, Tan YQ, Ma WJ, Yang Q, Wang JK, Cheng NS, Li FY. Prognostic factors and long-term outcomes of hilar cholangiocarcinoma: A single-institution experience in China. World J Gastroenterol 2016; 22(8): 2601-2610 [PMID: 26937148 DOI: 10.3748/wjg.v22.i8.2601] [Cited by in CrossRef: 38] [Cited by in F6Publishing: 37] [Article Influence: 7.6] [Reference Citation Analysis]
20 Xiang S, Lau WY, Chen XP. Hilar cholangiocarcinoma: controversies on the extent of surgical resection aiming at cure. Int J Colorectal Dis. 2015;30:159-171. [PMID: 25376337 DOI: 10.1007/s00384-014-2063-z] [Cited by in Crossref: 31] [Cited by in F6Publishing: 25] [Article Influence: 4.4] [Reference Citation Analysis]
21 Wang JK, Hu HJ, Shrestha A, Ma WJ, Yang Q, Liu F, Cheng NS, Li FY. Can preoperative and postoperative CA19-9 levels predict survival and early recurrence in patients with resectable hilar cholangiocarcinoma? Oncotarget 2017;8:45335-44. [PMID: 28484084 DOI: 10.18632/oncotarget.17336] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 4.3] [Reference Citation Analysis]
22 Coelen RJS, Vogel JA, Vroomen LGPH, Roos E, Busch ORC, van Delden OM, Delft FV, Heger M, van Hooft JE, Kazemier G, Klümpen HJ, van Lienden KP, Rauws EAJ, Scheffer HJ, Verheul HM, Vries J, Wilmink JW, Zonderhuis BM, Besselink MG, van Gulik TM, Meijerink MR. Ablation with irreversible electroporation in patients with advanced perihilar cholangiocarcinoma (ALPACA): a multicentre phase I/II feasibility study protocol. BMJ Open 2017;7:e015810. [PMID: 28864693 DOI: 10.1136/bmjopen-2016-015810] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 3.5] [Reference Citation Analysis]
23 Weijer R, Broekgaarden M, van Golen RF, Bulle E, Nieuwenhuis E, Jongejan A, Moerland PD, van Kampen AH, van Gulik TM, Heger M. Low-power photodynamic therapy induces survival signaling in perihilar cholangiocarcinoma cells. BMC Cancer 2015;15:1014. [PMID: 26705830 DOI: 10.1186/s12885-015-1994-2] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
24 Lim JH, Choi GH, Choi SH, Kim KS, Choi JS, Lee WJ. Liver resection for Bismuth type I and Type II hilar cholangiocarcinoma. World J Surg. 2013;37:829-837. [PMID: 23354922 DOI: 10.1007/s00268-013-1909-9] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 3.1] [Reference Citation Analysis]
25 Ebata T, Mizuno T, Yokoyama Y, Igami T, Sugawara G, Nagino M. Surgical resection for Bismuth type IV perihilar cholangiocarcinoma. Br J Surg. 2018;105:829-838. [PMID: 28488733 DOI: 10.1002/bjs.10556] [Cited by in Crossref: 47] [Cited by in F6Publishing: 42] [Article Influence: 11.8] [Reference Citation Analysis]
26 Coelen RJ, Ruys AT, Besselink MG, Busch OR, van Gulik TM. Diagnostic accuracy of staging laparoscopy for detecting metastasized or locally advanced perihilar cholangiocarcinoma: a systematic review and meta-analysis. Surg Endosc 2016;30:4163-73. [PMID: 26895909 DOI: 10.1007/s00464-016-4788-y] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 3.2] [Reference Citation Analysis]
27 Soares KC, Kamel I, Cosgrove DP, Herman JM, Pawlik TM. Hilar cholangiocarcinoma: diagnosis, treatment options, and management. Hepatobiliary Surg Nutr. 2014;3:18-34. [PMID: 24696835 DOI: 10.3978/j.issn.2304-3881.2014.02.05] [Cited by in F6Publishing: 46] [Reference Citation Analysis]
28 Lamarca A, Frizziero M, McNamara MG, Valle JW. Clinical and Translational Research Challenges in Biliary Tract Cancers. Curr Med Chem 2020;27:4756-77. [PMID: 31971102 DOI: 10.2174/0929867327666200123090153] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 12.0] [Reference Citation Analysis]
29 Zhang B, Dong W, Luo H, Zhu X, Chen L, Li C, Zhu P, Zhang W, Xiang S, Zhang W, Huang Z, Chen X. Surgical treatment of hepato-pancreato-biliary disease in China: the Tongji experience. Sci China Life Sci 2016;59:995-1005. [DOI: 10.1007/s11427-016-5104-8] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
30 Noji T, Tsuchikawa T, Mizota T, Okamura K, Nakamura T, Tamoto E, Shichinohe T, Hirano S. Surgery for recurrent biliary carcinoma: results for 27 recurrent cases. World J Surg Oncol 2015;13:82. [PMID: 25884694 DOI: 10.1186/s12957-015-0507-8] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.3] [Reference Citation Analysis]
31 Siddiqui A, Shahid H, Sarkar A, Cox K, Kowalski TE, Loren DE, Sharma A, Laing P, Birch M, Adler DG. Stage of Hilar Cholangiocarcinoma Predicts Recurrence of Biliary Obstruction in Patients With Metal Stents. Clinical Gastroenterology and Hepatology 2013;11:1169-73. [DOI: 10.1016/j.cgh.2013.05.035] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
32 Vugts JJA, Gaspersz MP, Roos E, Franken LC, Olthof PB, Coelen RJS, van Vugt JLA, Labeur TA, Brouwer L, Besselink MGH, IJzermans JNM, Darwish Murad S, van Gulik TM, de Jonge J, Polak WG, Busch ORC, Erdmann JL, Groot Koerkamp B, Buettner S. Eligibility for Liver Transplantation in Patients with Perihilar Cholangiocarcinoma.Ann Surg Oncol. 2021;28:1483-1492. [PMID: 32901308 DOI: 10.1245/s10434-020-09001-8] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
33 Hu HJ, Zhou RX, Shrestha A, Tan YQ, Ma WJ, Yang Q, Lu J, Wang JK, Zhou Y, Li FY. Relationship of tumor size with pathological and prognostic factors for hilar cholangiocarcinoma. Oncotarget 2017;8:105011-9. [PMID: 29285229 DOI: 10.18632/oncotarget.22054] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
34 Gaspersz MP, Buettner S, van Vugt JLA, de Jonge J, Polak WG, Doukas M, Ijzermans JNM, Koerkamp BG, Willemssen FEJA. Evaluation of the New American Joint Committee on Cancer Staging Manual 8th Edition for Perihilar Cholangiocarcinoma. J Gastrointest Surg 2020;24:1612-8. [PMID: 30756314 DOI: 10.1007/s11605-019-04127-x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
35 Oliveira IS, Kilcoyne A, Everett JM, Mino-Kenudson M, Harisinghani MG, Ganesan K. Cholangiocarcinoma: classification, diagnosis, staging, imaging features, and management. Abdom Radiol (NY). 2017;42:1637-1649. [PMID: 28271275 DOI: 10.1007/s00261-017-1094-7] [Cited by in Crossref: 40] [Cited by in F6Publishing: 39] [Article Influence: 10.0] [Reference Citation Analysis]